Tags

Type your tag names separated by a space and hit enter

Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers.
Clin Respir J. 2008 Jan; 2(1):17-25.CR

Abstract

INTRODUCTION

Inflammation is an important constituent of the pathology of chronic obstructive pulmonary disease (COPD), leading to alveolar destruction and airway remodelling.

OBJECTIVE

The aim of this study was to assess the difference in plasma biomarkers of inflammation between asymptomatic smokers and patients with COPD.

METHODS

We used commercially available enzyme-linked immunosorbent assay kits to measure the plasma levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), matrix metalloproteinase-9 (MMP-9), monocyte chemotactic protein-1 (MCP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1) and tissue inhibitor of metalloproteinase-2 (TIMP-2) on two occasions with a 2-week interval in patients with COPD (n = 20), asymptomatic smokers (n = 10) and healthy lifelong non-smokers (n = 10). The participants were characterised clinically, physiologically and by quantitative computed tomography by measuring the relative area of emphysema below -910 Hounsfield units (RA-910).

RESULTS

The results of the biomarker measurements on the two occasions were highly reproducible. Patients with COPD had significantly higher plasma levels of IL-8 (P = 0.004) and significantly lower levels of TIMP-1 (P = 0.02) than smokers and non-smokers. There was no statistically significant difference between the three groups in the level of TNF-alpha, MMP-9, MCP-1 and TIMP-2. The IL-8/TIMP-1 ratio correlated significantly with the degree of airway obstruction measured as forced expiratory volume in 1 second (FEV(1)) % predicted (r = -0.47, P < 0.01); with the diffusion capacity (r = -0.41, P < 0.01); and with the grade of emphysema measured as RA-910 (r = 0.39, P = 0.01).

CONCLUSION

These findings suggest that the measurement of plasma biomarkers, such as IL-8/TIMP-1, may aid to discriminate patients with COPD from smokers at lower risk of developing COPD.

Authors+Show Affiliations

Department of Cardiology and Respiratory Medicine, Hvidovre University Hospital, Copenhagen, Denmark. saher@dadlnet.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20298300

Citation

Shaker, Saher B., et al. "Identification of Patients With Chronic Obstructive Pulmonary Disease (COPD) By Measurement of Plasma Biomarkers." The Clinical Respiratory Journal, vol. 2, no. 1, 2008, pp. 17-25.
Shaker SB, von Wachenfeldt KA, Larsson S, et al. Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers. Clin Respir J. 2008;2(1):17-25.
Shaker, S. B., von Wachenfeldt, K. A., Larsson, S., Mile, I., Persdotter, S., Dahlbäck, M., Broberg, P., Stoel, B., Bach, K. S., Hestad, M., Fehniger, T. E., & Dirksen, A. (2008). Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers. The Clinical Respiratory Journal, 2(1), 17-25. https://doi.org/10.1111/j.1752-699X.2007.00032.x
Shaker SB, et al. Identification of Patients With Chronic Obstructive Pulmonary Disease (COPD) By Measurement of Plasma Biomarkers. Clin Respir J. 2008;2(1):17-25. PubMed PMID: 20298300.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers. AU - Shaker,Saher B, AU - von Wachenfeldt,Karin A, AU - Larsson,Susanne, AU - Mile,Iréne, AU - Persdotter,Sofia, AU - Dahlbäck,Magnus, AU - Broberg,Per, AU - Stoel,Berend, AU - Bach,Karen S, AU - Hestad,Marianne, AU - Fehniger,Thomas E, AU - Dirksen,Asger, PY - 2010/3/20/entrez PY - 2008/1/1/pubmed PY - 2010/7/20/medline SP - 17 EP - 25 JF - The clinical respiratory journal JO - Clin Respir J VL - 2 IS - 1 N2 - INTRODUCTION: Inflammation is an important constituent of the pathology of chronic obstructive pulmonary disease (COPD), leading to alveolar destruction and airway remodelling. OBJECTIVE: The aim of this study was to assess the difference in plasma biomarkers of inflammation between asymptomatic smokers and patients with COPD. METHODS: We used commercially available enzyme-linked immunosorbent assay kits to measure the plasma levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), matrix metalloproteinase-9 (MMP-9), monocyte chemotactic protein-1 (MCP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1) and tissue inhibitor of metalloproteinase-2 (TIMP-2) on two occasions with a 2-week interval in patients with COPD (n = 20), asymptomatic smokers (n = 10) and healthy lifelong non-smokers (n = 10). The participants were characterised clinically, physiologically and by quantitative computed tomography by measuring the relative area of emphysema below -910 Hounsfield units (RA-910). RESULTS: The results of the biomarker measurements on the two occasions were highly reproducible. Patients with COPD had significantly higher plasma levels of IL-8 (P = 0.004) and significantly lower levels of TIMP-1 (P = 0.02) than smokers and non-smokers. There was no statistically significant difference between the three groups in the level of TNF-alpha, MMP-9, MCP-1 and TIMP-2. The IL-8/TIMP-1 ratio correlated significantly with the degree of airway obstruction measured as forced expiratory volume in 1 second (FEV(1)) % predicted (r = -0.47, P < 0.01); with the diffusion capacity (r = -0.41, P < 0.01); and with the grade of emphysema measured as RA-910 (r = 0.39, P = 0.01). CONCLUSION: These findings suggest that the measurement of plasma biomarkers, such as IL-8/TIMP-1, may aid to discriminate patients with COPD from smokers at lower risk of developing COPD. SN - 1752-699X UR - https://www.unboundmedicine.com/medline/citation/20298300/Identification_of_patients_with_chronic_obstructive_pulmonary_disease__COPD__by_measurement_of_plasma_biomarkers_ L2 - https://doi.org/10.1111/j.1752-699X.2007.00032.x DB - PRIME DP - Unbound Medicine ER -